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Available online 30 June 2016In Alzheimer's disease (AD), tau undergoes numerousmodiﬁcations, including increased phosphorylation at ser-
ine-422 (pS422). In the human brain, pS422 tau protein is found in prodromal AD, correlates well with cognitive
decline and neuropil thread pathology, and appears associated with increased oligomer formation and exposure
of the N-terminal phosphatase-activating domain (PAD). However, whether S422 phosphorylation contributes
to toxic mechanisms associated with disease-related forms of tau remains unknown. Here, we report that
S422-pseudophosphorylated tau (S422E) lengthens the nucleation phase of aggregationwithout altering the ex-
tent of aggregation or the types of aggregates formed. When compared to unmodiﬁed tau aggregates, the S422E
modiﬁcation signiﬁcantly increased the amount of SDS-stable tau dimers, despite similar levels of immunoreac-
tivity with an oligomer-selective antibody (TOC1) and another antibody that reports PAD exposure (TNT1). Ves-
icle motility assays in isolated squid axoplasm further revealed that S422E taumonomers inhibited anterograde,
kinesin-1 dependent fast axonal transport (FAT). Unexpectedly, and unlike unmodiﬁed tau aggregates, which se-
lectively inhibit anterograde FAT, aggregates composed of S422E tau were found to inhibit both anterograde and
retrograde FAT. Highlighting the relevance of these ﬁndings to human disease, pS422 tau was found to colocalize
with tau oligomers andwith a fraction of tau showing increased PAD exposure in the human AD brain. This study
identiﬁes novel effects of pS422 on tau biochemical properties, including prolonged nucleation and enhanced
dimer formation, which correlate with a distinct inhibitory effect on FAT. Taken together, these ﬁndings identify
a novel mechanistic basis by which pS422 confers upon tau a toxic effect that may directly contribute to axonal
dysfunction in AD and other tauopathies.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Tau is a microtubule-associated protein and important component
of the neuronal cytoskeleton that plays a role in the regulation of signal-
ing pathways within an axon (Kanaan et al., 2013). Under pathological
conditions, tau transitions from a solublemonomeric state to oligomeric
and ﬁlamentous aggregates, which accumulate as neuroﬁbrillarytional Science and Molecular
E, Grand Rapids, MI 49503, USA.
naan).
y of California, Davis, CA 95616,
. This is an open access article undertangles (NFTs), neuropil threads, and neuritic plaques (Grundke-Iqbal
et al., 1986a,b; Kosik et al., 1986; Wood et al., 1986). The accumulation
of tau aggregates in various morphological states is characteristic of a
number of neurodegenerative diseases referred to as tauopathies, in-
cluding Alzheimer's disease (AD) (Spillantini and Goedert, 1998). Path-
ological tau inclusions in these diseases display numerous abnormal
alterations, some of which can facilitate aggregation and attenuate mi-
crotubule binding and stabilization (Bierer et al., 1995; Biernat et al.,
1993; Drewes et al., 1995). At least 25 threonine/serine sites are phos-
phorylated in ﬁlamentous tau (Morishima-Kawashima et al., 1995);
however, many of these phosphorylation sites are shared with normal
tau protein derived from human brain biopsies (Matsuo et al., 1994).
Additionally, NFT formation follows a prescribed sequence of events
during disease progression; some sites are phosphorylated early in thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
319C.T. Tiernan et al. / Experimental Neurology 283 (2016) 318–329pathogenic process, whereas other sites are not phosphorylated until
after NFTs have already formed (Kimura et al., 1996; Stoothoff and
Johnson, 2005). Hence, speciﬁc tauphosphorylation events contributing
to disease-causing processes remain unclear. From this, it is essential to
understand the effect of individual phosphorylation sites on tau aggre-
gation and neurodegenerative mechanisms.
C-terminal phosphorylation of tau at serine-422 (pS422) is a dis-
ease-related modiﬁcation that occurs early in the progression of AD
(Guillozet-Bongaarts et al., 2006; Kimura et al., 1996; Vana et al.,
2011). In AD, pS422 tau is found in pre-tangle neurons (Guillozet-
Bongaarts et al., 2006), and appearance of the pS422 epitope is a
stronger correlate of disease neuropathology and cognitive decline
than mature NFT deposition (Vana et al., 2011). Moreover, the lack
of pS422 tau in cognitively intact control brain samples further sup-
ports the disease-speciﬁcity of pS422 (Bussière et al., 1999;
Hasegawa et al., 1996). Evidence from animal models of AD supports
this conclusion. For example, appearance of the pS422 epitope is de-
pendent upon β-amyloid-induced NFT formation in transgenic mice
expressing mutant P301L human tau protein (Deters et al., 2009;
Gotz et al., 2001; Grueninger et al., 2010).
Recent studies from our group and others have implicated two path-
ogenic events associatedwith disease-related forms of tau. First, confor-
mational changes in tau that aberrantly expose the phosphatase-
activating domain (PAD, amino acids 2–18) activate a PP1/GSK3β sig-
naling pathways and promote inhibition of anterograde fast axonal
transport (FAT) (Kanaan et al., 2011; LaPointe et al., 2009b). The tau
N-terminal 1 (TNT1) antibody, a monoclonal antibody raised against
amino acids 2–18, demonstrates that PAD exposure is a disease-related
event (Kanaan et al., 2011, 2012). The pattern of TNT1-immunoreactiv-
ity indicates diffuse, granular cytoplasmic staining in pretangle neurons
preceding the appearance of the early phospho-epitope AT8 in post-
mortem human tissue (Kanaan et al., 2011). Second, preﬁbrillar oligo-
meric species of tau are more potent inducers of neurodegeneration
than ﬁbrillar tau aggregates (Berger et al., 2007; Kopeikina et al.,
2011; Maeda et al., 2007; Patterson et al., 2011a; Sahara et al., 2013).
In this regard, a monoclonal antibody that preferentially labels tau olig-
omers (tau oligomeric complex 1; TOC1) (Grundke-Iqbal et al., 1986a,b;
Kosik et al., 1986; Patterson et al., 2011a;Ward et al., 2013;Wood et al.,
1986) displays elevated immunoreactivity in prodromal AD brains
(mild cognitive impairment) (Mufson et al., 2014; Spillantini and
Goedert, 1998), and does not colocalize with later events in tangle for-
mation, such as truncation at residue 391 or formation of β-sheet struc-
tures (Bierer et al., 1995; Biernat et al., 1993; Drewes et al., 1995;
Patterson et al., 2011a). Interestingly, pS422 accompanies PADexposure
and tau oligomer formation in early tau pathology observed in several
brain regions (e.g. medial temporal lobe, temporal cortex and choliner-
gic basal forebrain) of Braak I–VI cases (Kanaan et al., 2016;
Morishima-Kawashima et al., 1995; Mufson et al., 2014; Patterson et
al., 2011a). However, whether pS422modulates PAD exposure or oligo-
mer formation remains unknown.
The present study sought to determine whether S422 phosphoryla-
tionmodulates tau aggregation, PAD exposure, oligomer formation, and
the toxic effect of aggregated tau on FAT. We present evidence indicat-
ing that pseudophosphorylation at S422 (S422E) lengthens the nucle-
ation phase of tau aggregation kinetics, without altering the overall
extent of aggregation or the types of aggregates formed. We also dem-
onstrate that, compared to unmodiﬁed tau aggregates, the S422E mod-
iﬁcation enhances the formation of SDS-resistant dimers without
altering exposure of the TNT1 or TOC1 epitopes. Using vesicle motility
assays in isolated squid axoplasm, we further report that S422E mono-
mers and aggregates inhibit FAT. Lastly, we establish that the tau species
isolated from human AD brain containing the pS422 modiﬁcation also
have PAD exposed (TNT1 reactive) and are in oligomeric conformations
(TOC1 reactive). Collectively, these results provide evidence of a func-
tional role for the pS422 disease-related modiﬁcation in mechanisms
of tau toxicity relevant to AD and other tauopathies.2. Materials & methods
2.1. Recombinant tau proteins
Full-length tau protein (hT40) corresponds to the longest isoform
in the adult human brain, consisting of 441 amino acids and four mi-
crotubule-binding repeats. Pseudophosphorylation (i.e., switching a
serine to a glutamate) was used to mimic phosphorylation at posi-
tion 422 in tau. Pseudophosphorylation is a routine approach to ex-
amine both single and multiple phosphorylation residues on the tau
protein (Guillozet-Bongaarts et al., 2006; Jeganathan et al., 2008;
Kanaan et al., 2011, 2012; LaPointe et al., 2009a; Matsuo et al., 1994;
Necula and Kuret, 2005). Pseudophosphorylated S422E tau was gener-
atedusingmutagenesis of the hT40 construct per themanufacturer's in-
structions (QuikChange Lightning Multi Site-Directed Mutagenesis Kit,
Agilent Technologies, 210515). The forward primer used in this reaction
was: CAGCATCGACATGGTAGACGAGCCCCAGCTCGCCACGCTAG. pT7c
plasmid DNAs containing either hT40 or S422E were ampliﬁed in
XL10-Gold ultracompetent Escherichia coli, puriﬁed using the PureLink
Quick Plasmid Miniprep Kit (Invitrogen, K2100), and veriﬁed by DNA
sequencing. Proteins were expressed in T7 Express supercompetent
Escherichia coli, and puriﬁed through C-terminal His-tag metal afﬁnity
chromatography (Talon resin, Clontech, 635502) followed by size ex-
clusion chromatography using an S200 26/60 column (GE Healthcare,
17-1195-01) as previously described (Carmel et al., 1996; Kimura et
al., 1996; Stoothoff and Johnson, 2005).2.2. In vitro tau polymerization reaction
Tau polymerization was induced with arachidonic acid (ARA; Cay-
man Chemical, 90010) as previously described (Gamblin et al., 2000;
Guillozet-Bongaarts et al., 2006; Kimura et al., 1996; LaPointe et al.,
2009a; Vana et al., 2011). Brieﬂy, recombinant tau (2 μM)was incubated
in polymerization buffer (5 mM dithiothreitol, 100 mM NaCl, 0.1 mM
EDTA, 10 mM HEPES, pH 7.6) with 75 μM ARA (ﬁnal concentration) at
room temperature for 6 h. ARA was stored at−20 °C, and working so-
lutionswere prepared in 100% ethanol immediately prior to use. Control
(monomer) samples were prepared in polymerization buffer with ARA
vehicle (i.e., 100% ethanol). A combination of right angle laser light scat-
ter, thioﬂavin S (ThS), and transmission electron microscopy was used
to validate tau aggregation.2.3. Right angle laser light scatter (LLS) assay
Tau polymerization was monitored in real-time by measuring the
intensity of right angle light scatter (iS; Gamblin et al., 2000;
Guillozet-Bongaarts et al., 2006). A 475 nm laser (B&W Tek, Inc.,
BWI-475-20-E) was used to illuminate polymerization reactions. Im-
ages of scattered light were captured throughout the 6 h polymeriza-
tion reaction using a high sensitivity CMOS digital camera (Thor Labs,
DCC1240M) and imaging software uc480 Viewer version 4.2. Images
were collected using an exposure time of 175.15 ms, a frame rate of
4.01 fps, and a pixel clock of 11 MHz. Individual images were imported
into Photoshop CS5 Version 12.1 (Adobe Systems, Inc.) where the mar-
quee tool was used to select a region of interest (75 × 10 pixels) within
the scattered light near the middle of the cuvette. The intensity of
scattered light was obtained using the histogram feature. The back-
ground intensity was subtracted bymeasuring scattering in the cuvette
prior to the addition of ARA (Gamblin et al., 2000; Vana et al., 2011).
Each experiment was repeated ﬁve independent times, and back-
ground-corrected light scatter data were plotted as a function of time.
The polymerization kinetics curve was best ﬁt with the sigmoidal
Gompertz equation (Bussière et al., 1999; Hasegawa et al., 1996;
Necula and Kuret, 2004a; Winsor, 1932).
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A 0.0175% solution of ThS (Sigma, #T1892) was prepared on the
day of each experiment and ﬁltered using a 0.2 μm syringe ﬁlter be-
fore use. Tomeasure ThS ﬂuorescence, 6 μl of 0.0175% ThS was added
to 150 μl of 2 μM aggregated tau (hT40 or S422E) in a black 96-well
plate (Fisher Scientiﬁc, 06-443-2), such that the ﬁnal concentration
of ThS was 0.0007%. Fluorescence measurements were performed at
25 °C in a GloMax Multi Detection System (Promega) with an excitation
wavelength of 490 nmand an emissionwavelength of 510–570nm. Each
experiment was repeated three independent times. To compare mea-
surements from independent experiments, background ﬂuorescence
was measured in wells containing tau (hT40 or S422E) + vehicle (etha-
nol), and subtracted from each respective treatment condition.
2.5. Transmission electron microscopy (TEM)
Aliquots of polymerized tau samples were ﬁxed with 2% glutaralde-
hyde, spotted onto 300mesh Formvar carbon coated copper grids (Elec-
tron Microscopy Sciences, 215-412-8400), and negatively stained with
2%uranyl acetate. Gridswere examinedwith a JEOL JEM-1400 Plus elec-
tronmicroscope at 80 kV and ×10,000magniﬁcation. Images were cap-
tured with an AMT XR81 digital camera and AMT software version
602.6 (Advanced Microscopy Techniques). Tau samples were diluted
to a ﬁnal concentration of 1.6 μM to capture representative images of
each polymerization reaction, or diluted to a ﬁnal concentration of
0.2 μM for quantitative TEM analysis. A higher dilution was used for
the quantitative analysis to obtain samples with discrete, non-overlap-
ping aggregates.
Images were processed using ImageJ to measure total aggregate
mass, individual aggregate area, aggregate number, and individual
aggregate lengths (Supplementary Fig. 1, Supplementary Table 1).
For the individual aggregate measures (i.e., number and length) ob-
jects were separated into three categories based on area; 1) oligo-
mers were b1000 nm2, 2) short ﬁlaments were 1000–5000 nm2, or
3) long ﬁlaments were N5000 nm2. All images were captured at
×10,000 magniﬁcation with a standard beam intensity and gain for
consistency across samples. A macro was used in ImageJ to measure
total aggregate mass, individual aggregate area and aggregate num-
ber. The scale was set at 373.5 pixels equal to 400 nm. Images were
smoothed twice to eliminate small variations in estimations of object
area, and auto threshold was used to distinguish aggregates over
background. Total mass of aggregated tau was determined by sum-
mating the area of individual aggregates (nm2) covering the ﬁeld.
Aggregate counts were performed for three populations of aggre-
gates sorted by area: oligomers ≤ 1000 nm2, short ﬁlaments =
1000–5000 nm2, and long ﬁlaments ≥ 5000 nm2. Aggregate length
was not an output of the ImageJ macro, thus these measurements
were made manually in ImageJ by measuring the distance along
the longest axis of individual oligomers (100 per sample), short ﬁla-
ments (average of 24 per sample) and long ﬁlaments (average of 50
per sample). Each experiment was repeated three independent
times, and ﬁve ﬁelds from each sample were randomly captured dur-
ing each experiment and used for analysis.
2.6. Soluble tau extraction from fresh frozen human tissue
Soluble tau was prepared from frontal cortex tissue of non-de-
mented control (n = 6; age: mean = 83 yrs, range = 75–95 yrs;
sex: 4 female, 2 male; Braak stage II–III) and AD cases (n = 6; age:
mean = 84 yrs, range = 69–93 yrs; sex: 0 female, 6 male; Braak
stage VI) as described previously (Deters et al., 2009; Gotz et al.,
2001; Grueninger et al., 2010; Kanaan et al., 2016). Brieﬂy, tissue
pieces from cortex (0.5–1 g) were homogenized on ice in ten vol-
umes (1 g = 10 ml) of brain homogenization buffer (50 mM Tris
pH 7.4, 274 mM NaCl, 5 mM KCl, 1 mM PMSF, and 10 μg/ml each ofpepstatin, leupeptin, bestatin, and aprotinin). The soluble tau frac-
tion was collected in the supernatant following centrifugation at
27,000 ×g for 20 min at 4 °C. The samples were assayed for total pro-
tein concentration using the Lowry protein assay and stored at−80 °
C until used in sandwich ELISAs for analysis (see below).2.7. Tau sandwich enzyme-linked immunosorbent assays (ELISAs)
A novel sandwich ELISA was developed to measure the relative
levels of oligomer formation and PAD exposure in recombinant tau pro-
teins and pS422-containing tau species in the frontal cortex from
human brains samples. All steps were performed at room temperature.
Washing was performed between each step using 200 μl/well of ELISA
wash buffer (100 mM borate acid, 25 mM sodium borate, 75 mM
NaCl, 0.25 mM thimerosal, 0.4% (w/v) bovine serum albumin, 0.05%
(v/v) Tween-20), and all other steps were performed using 50 μl so-
lution/well. For recombinant tau protein sandwich ELISAs, the fol-
lowing capture antibodies were used: Tau5, TNT1, or TOC1. Tau5 is
a monoclonal mouse IgG1 raised against bovine tau, with a continu-
ous epitope between amino acids 215–225. Tau5 is a pan-tau anti-
body that labels monomeric and aggregated tau equally well
(Carmel et al., 1996; Kanaan et al., 2011; LaPointe et al., 2009b;
LoPresti et al., 1995; Porzig et al., 2007). TNT1 is a monoclonal
mouse IgG1 directed against N-terminal amino acids 2–18
(AEPRQEFEVMEDHAGTY), the PAD (Kanaan et al., 2011, 2012). In
native assays, reactivity of TNT1 is dependent upon conformational
display of PAD, which is a disease-speciﬁc event (Kanaan et al.,
2011, 2012). TOC1 is a monoclonal mouse IgM raised against tau di-
mers (Berger et al., 2007; Kopeikina et al., 2011; Maeda et al., 2007;
Patterson et al., 2011a; Sahara et al., 2013). The TOC1 epitope (amino
acids 209–224) is conformation dependent as it is revealed upon di-
merization and oligomerization of tau (Ward et al., 2013). High bind-
ing 96-well microplates (Fisher Scientiﬁc, 07-200-35) were coated
with Tau5 (1 μg/ml), TNT1 (2 μg/ml) or TOC1 (2 μg/ml) capture anti-
body diluted in borate saline (100 mM borate acid, 25 mM sodium
borate, 75 mM NaCl, 0.25 mM thimerosal) for 60 min. Plates were
washed twice with ELISA wash buffer, and then blocked for 60 min
with ELISA wash containing 5% non-fat dry milk (blocking reagent).
Each well was washed twice and then recombinant tau samples
were added to each well for 90 min. Recombinant hT40 and S422E
tau monomers or aggregates from the in vitro polymerization assays
were diluted with polymerization buffer to a ﬁnal concentration of
5 nM (Tau5 and TNT1 assays) or 20 nM (TOC1 assay). Titer assays
were performed for each capture antibody sandwich ELISA to ensure
recombinant tau protein concentrations produced signal within the
linear range. Wells were rinsed 3 times with ELISA wash and then in-
cubated for 90 min with the rabbit polyclonal pan-tau antibody R1
(Berry et al., 2004) diluted 1:20,000 in blocking reagent, as the de-
tection antibody. Wells were washed 3 times, and then incubated
for 60 min with goat anti-rabbit IgG conjugated to horseradish per-
oxidase (1:5000; Vector Labs, PI-1000) diluted in blocking reagent.
Wells were washed 3 times, and assays were developed using
3,3′,5,5′-tetramethylbenzidine (TMB; Sigma) for 15 min (Tau5,
TNT1) or 30 min (TOC1). Development reactions were stopped
with 3.5% sulfuric acid and absorbance was read at 450 nm on a
SpectraMax Plus 384 microplate reader (Molecular Devices). The
amount of total tau applied in the assay was known and equivalent
between groups since these are recombinant protein samples, but
absorbance (A) is not a linear measure (i.e., A = Log10 (1/transmit-
tance) and not useful for comparing across samples (e.g. A = 0.3 is
50% light absorbed, A = 1 is 90% light absorbed and A = 2 is 99%
light absorbed). Thus, the absorbance data were converted to per-
cent light absorbed (a linear scale) using the following equation
%A = (1–10−x) × 100, where x is absorbance. The percent light
absorbed data were used for statistical comparisons across groups.
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and tau oligomers in pS422-containing tau species in the soluble tau
fractions of the frontal cortex from control and AD brains (Kanaan et
al., 2016). Tau species containing pS422 protein were captured by coat-
ing ELISA microplates for 60 min with rabbit anti-pS422 antibody
(Abcam, ab79415, diluted to 2 μg/ml in borate saline). Plates were
rinsed twice, blocked for 60 min with blocking reagent, and rinsed
twice before samples were added to the well for 90 min. Human brain
extracts were diluted to a ﬁnal total protein concentration of 0.4 μg/μl
(i.e., 20 μg/well). The optimal protein amount for the soluble tau fraction
was determined by titering to ensure the ELISAswere performedwithin
the linear range of reactivity.Wellswere rinsed twice, and then incubat-
ed for 90 min with Tau5 (0.005 μg/ml), TNT1 (0.01 μg/ml) or TOC1
(1 μg/ml) as the detection antibodies (diluted in blocking reagent).
Wells were rinsed 3 times and incubated for 90 min with horse anti-
mouse IgG conjugated to horseradish peroxidase (Vector Labs, PI-
2000) or goat anti-mouse IgM-speciﬁc conjugated to horseradish per-
oxidase (Jackson, 115-035-020) diluted (0.2 μg/ml) in blocking reagent.
The wells were rinsed 3 times, signal was detected by developing TMB
for 6 min (TOC1) or 30 min (Tau5 and TNT1), and then the reaction
was stopped using 3.5% sulfuric acid. Tau standard ELISAs were per-
formed with human sample sandwich ELISAs to estimate the amount
of tau captured by anti-pS422 and detected with Tau5, TNT1 or TOC1.
For the tau standards, a serial dilution of recombinant full-length
human tau protein ranging from 100 to 3.13 ng was bound to the
ELISA plate for 60 min, blocked as above, and detected using either
Tau5, TNT1 or TOC1 antibodies and HRP-secondary antibodies exactly
as in the recombinant protein sandwich ELISAs above. Each standard
was run in duplicate and developed simultaneously with the sandwich
ELISAs to ensure accurate interpolation of unknown tau amounts. The
standard curve data were log10 transformed and best ﬁt to a sigmoidal
curve (r2 = 0.99 for all three). This provided a standard curve of absor-
bance values thatwere derived fromTau5, TNT1 or TOC1 reactivitywith
known amounts of tau protein. The quantity of tau (ng) in each human
sample was interpolated from the tau standard curves and then con-
verted to a concentration of ng/μl by dividing the interpolated quantity
by the volume of the sample used (i.e., 50 μl). Finally, the data (i.e., con-
centrations of tau) were normalized to reduce skewness using logarith-
mic transformations and then used for statistical comparisons.
2.8. Immunoblotting
Monomeric and aggregated tau samples were prepared in Laemmli
sample buffer (20mMTris pH 6.8, 6% glycerol (v/v). 1.6% sodium dode-
cyl sulfate (v/v), 0.85% 2-mercaptoethanol (v/v), 0.002% bromophenol
blue (v/v)), incubated at 90 °C for 5 min, separated by SDS-PAGE
using 4–20% Criterion TGX precast gels (Bio-Rad Laboratories, Inc.,
5671094) and transferred to 0.22 μm nitrocellulose membranes (Pall
Corporation, 66485). Membranes were blocked with 2% non-fat dry
milk in Tris-buffered saline (TBS; 50 mM Tris, 150 mM NaCl, pH 7.4),
and incubated overnight at 4 °C in Tau13 antibody (1:50,000), a
mouse monoclonal IgG1 antibody against the N-terminus of tau
(García-Sierra et al., 2003). Membranes were rinsed four times in
TBS+ 0.1% Tween 20, and developed with the afﬁnity-puriﬁed second-
ary antibody conjugated to IRDye 680RD goat anti-mouse IgG (H + L)
(LiCor, 925-68070). Image acquisition and intensity measurements
were performed using a LiCor Odyssey system.
2.9. Squid axoplasm motility assay
FAT was evaluated in freshly extruded squid axoplasm from giant
squid axon (Loligo pealii; Marine Biological Laboratory, Woods Hole,
MA) as previously described (Brady et al., 1993; Morﬁni et al., 2007;
Song et al., 2016). Tau protein (monomer or aggregate) was diluted in
X/2 buffer (175 mM potassium aspartate, 65 mM taurine, 35 mM beta-
ine, 25mM glycine, 10 mMHEPES, 6.5 mMMgCl2, 5 mM EGTA, 1.5 mMCaCl2, 0.5mMglucose, 10mMadenosine triphosphate, pH 7.2) and per-
fused into isolated axoplasm at a ﬁnal concentration of 2 μM. The tau
protein concentration of 2 μMwas chosen speciﬁcally because it is with-
in the physiological range of tau in the brain (Alonso et al., 1996; King et
al., 1999). Motility was analyzed using a Zeiss Axiomat microscope
equipped with a 100× (1.3 numerical aperture) objective and differen-
tial interference contrast optics. Images were obtained using a
Hammamatsu C2400 CCD with an Argus 20 for image adjustment and
the video was further processed using a Hamamatsu Photonics Micros-
copy C2117 video manipulator for generation of calibrated cursors and
scale bars (Song et al., 2016). Anterograde and retrograde FAT were
measured by matching calibrated cursor movements to the speed of
vesicles moving in the axoplasm preparation. Vesicle motility wasmea-
sured for 50 min after perfusion and data were plotted as a function of
time. Full-length hT40 monomer was used as the control group since
no changes are observed for this experimental group when compared
to buffer control-perfused axoplasms (LaPointe et al., 2009b; Morﬁni
et al., 2007). Two comparisons weremade between groups: i) the aver-
age velocity of transport over the last 20min of the assaywas compared
to measure the extent of inhibition across treatment groups, and ii) the
rate of change in transport velocity over the entire 50 min assay was
evaluated by comparing the slope of the linear regression curve ﬁt for
each group.2.10. Triple-label immunoﬂuorescence (IF) for confocal microscopy
Triple-label IF was used to characterize co-localization between tau
phosphorylated at S422, PAD exposed tau and oligomeric tau. Tissue
sections from age-matched, non-demented controls (n = 6; age:
mean = 81 yrs, range = 73–91 yrs; sex: 1 female, 5 males; Braak
stage I–III) and severe AD cases (n= 6; age: mean = 83, range = 60–
92 yrs; sex: 4 female, 2 males; Braak stage V–VI) were processed for tri-
ple-label IF using the TNT1 (mouse IgG1), TOC1 (mouse IgM) andpS422
(rabbit) antibodies according to published methods (Kanaan et al.,
2016). The sections were incubated overnight at 4 °C in a primary anti-
body solution containing TNT1 (1:30,000), TOC1 (1:2000) and pS422
(1:1000) antibodies followed by incubation in a secondary antibody
solution of Alexa Fluor 488 goat anti-mouse IgG1-speciﬁc (Invitrogen,
A-21121), Alexa Fluor 568 goat anti-mouse IgM-speciﬁc (Invitrogen,
A-21043), and Alexa Fluor 405 goat anti-rabbit speciﬁc (Invitrogen, A-
31556) antibodies (all diluted 1:500) for 2 h. Following the stainingpro-
cedure, sections were mounted on microscope slides, autoﬂuorescence
was blocked using sudan black as described (Kanaan et al., 2007,
2011, 2012), and coverslipped using hardset Vectashield mounting
media. Control sections with one of the three primary antibodies omit-
ted conﬁrmed that each secondary label was speciﬁc to the appropriate
primary antibody (i.e., no staining was observed with the ﬂuorophore
for the omitted antibody; data not shown). A Nikon A1+ laser scanning
confocal microscope system equipped with solid-state lasers (488, 561,
and 640) and Nikon Elements AR software were used to acquire image
z-stacks (0.5 μm step size), and the images (maximum intensity projec-
tions) were prepared for publication using Adobe Photoshop and
Illustrator.2.11. Statistics
All experiments were repeated at least three times (see ﬁgure
legends). All experiments were analyzed by Student's t-test or two-
way analysis of variance as indicated in ﬁgure legends. When overall
signiﬁcance was achieved, the Holm-Sidak post-hoc test was used to
make all possible comparisons. Data were expressed as mean± SEM.
All tests were two-tailed, and signiﬁcance was set at p ≤ 0.05.
GraphPad Prism 6 software (GraphPad Software, Inc.) was used for
all statistical tests.
Table 1
Polymerization kinetics of hT40 and S422E ﬁt to the Gompertz sigmoidal function.
Protein
Lag time
(min)
kapparent
(time−1)
Maximum (pixel
intensity) r2 n
hT40 4.6 ± 0.6 0.154 ± 0.005 122.5 ± 1.2 0.9658 4
S422E 8.5 ± 1.7 0.135 ± 0.005 134.5 ± 1.7 0.9452 4
Lag time: indicates the time until detectable polymerization signal is present.
kapparent (arbitrary units): proportional to the maximum rate of polymerization.
Maximum: LLS signal after 6 h.
Values are expressed as mean ± SEM.
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3.1. S422E lengthens the nucleation phase of aggregate formation in vitro,
but overall extent of aggregation and the types of aggregate species formed
are similar to wild-type tau
Recombinant tau protein (2 μM)was induced to aggregatewith ARA
(75 μM) to determine whether pseudophosphorylation at S422 inﬂu-
ences tau polymerization characteristics. Aggregation was monitored
in real-time for 360 min by right-angle LLS (Fig. 1). The data were best
ﬁt to the Gompertz sigmoidal function to evaluate polymerization ki-
netics (Table 1). The time to initiate polymerization (i.e., lag time or nu-
cleation time) for S422E tau (8.5± 1.7min)was 1.85 times longer than
hT40 tau (4.6 ± 0.6 min). However, the rate of polymerization
(kapparent) did not differ between hT40 tau and S422E tau. At 360 min,
a similar intensity of light scattering was observed for hT40 (122.5 ±
1.2) and S422E tau (134.5± 1.7) indicating that the extent of aggregate
formation was comparable between these two proteins. ThS ﬂuores-
cence, measured at 360min, alsowas comparable between hT40 aggre-
gates (946.4 ± 73.8) and S422E aggregates (927.9 ± 63.7).
Quantitative analysis of polymerized hT40 and S422E samples
was performed on TEM micrographs to verify the results of LLS as-
says and evaluate whether the S422E modiﬁcation modulates the
types of aggregates formed by hT40 (Fig. 2A–E). Total aggregate
mass (Fig. 2C; t4 = 1.73, p = 0.16) and mean aggregate length (Fig.
2D; t4 = 0.82, p = 0.46) were not signiﬁcantly different between
hT40 and S422E tau constructs. Aggregates were sorted by area
into oligomers, short ﬁlaments and long ﬁlaments for comparisons
between hT40 and S422E samples. Area measurements aligned
well with previously deﬁned criteria for oligomers using length
(i.e., b50 nm) (Patterson et al., 2011a). Previously, ﬁlaments were
deﬁned as aggregates N50 nm in length (Patterson et al., 2011a),
but here we further segregated ﬁlaments into short and long catego-
ries using area (short: 1000–5000 nm2 corresponding to ~35–
275 nm lengths and long: N5000 nm2 corresponding to ~200–
1800 nm lengths) to better characterize these two populations of
ﬁlaments (Supplementary Fig. 1, Supplementary Table 1). For both
tau constructs, there were signiﬁcantly more oligomer-type aggre-
gates than short or long ﬁlaments formed, but no signiﬁcant differ-
ence between the numbers of short or long ﬁlament (Fig. 2E;
F(2,12) = 86.64, p b 0.0001). S422E did not differ signiﬁcantly from
hT40 in the number of oligomers, short ﬁlaments, or long ﬁlaments
formed (F(1,12) = 0.05, p = 0.83).
3.2. S422 pseudophosphorylation does not alter the extent of PAD exposure
and oligomer formation in vitro
We used a sandwich ELISA to determine whether monomer and
aggregated hT40 and S422E tau differ in the extent of PAD exposureFig. 1. Pseudophosphorylation of S422 slows the initiation of tau polymerization but does not
(open circles; n = 4) and S422E (closed triangles; n= 4) during the entire 360 min reaction
illustrate the differences in lag time. Polymerization was measured as intensity of scattered li
shown in Table 1).and oligomer formation (Fig. 3). Total tau was assessed using Tau5
sandwich ELISAs, and as expected the monomer and aggregate sam-
ples were equivalent between all groups (Fig. 3A; hT40 vs. S422E,
F(1,12) = 3.09, p = 0.10; monomer vs. aggregate, F(1,12) = 1.80,
p = 0.20). Compared to monomers, aggregation signiﬁcantly in-
creased PAD exposure for both hT40 and S422E samples (Fig. 3B;
F(1,12) = 685.8, p b 0.0001), as indicated by increased TNT1 reactivi-
ty. Aggregation also signiﬁcantly increased oligomer formation
(TOC1 reactivity) compared to monomers in both hT40 and S422E
samples (Fig. 3C; F(1,12) = 109.3, p b 0.0001). However, there were
no differences in either TNT1 (F(1,12) = 0.17, p = 0.69) or TOC1
(F(1,12) = 0.02, p = 0.89) immunoreactivity between hT40 and
S422E monomers or aggregates. The robust differences between
monomers and aggregates, but lack of difference between hT40 and
S422E constructs, were consistent across a range of sample concen-
trations (1.56–200 nM; data not shown).3.3. Pseudophosphorylation at S422 enhances the formation of SDS-stable
tau dimers
Next, we sought to investigate whether pseudophosphorylation
at S422 altered the formation of SDS-stable tau dimers following ag-
gregation in vitro (Patterson et al., 2011a). Immunoblotting with the
high afﬁnity total tau antibody, Tau13, detected tau monomers
(~64 kDa) and apparent 180 kDa tau dimers (Patterson et al.,
2011a; Fig. 4A). The 64 kDa molecular weight band was observed
in hT40 and S422E monomer and aggregated samples as expected,
and signal intensity was not signiﬁcantly different between either
tau construct (hT40 vs. S422E, F(1,12) = 0.03, p=0.86) or tau species
(monomer vs. aggregate, F(1,12) = 0.02, p = 0.88) (Fig. 4B). In con-
trast, aggregation of either hT40 or S422E signiﬁcantly increased
the amount of SDS-stable dimers at 180 kDa (Fig. 4C; F(1,12) =
110.0; p b 0.0001), as compared to the levels of these species in the
respective monomer samples. Furthermore, S422E aggregation sig-
niﬁcantly increased the amount of SDS-stable dimers compared to
hT40 aggregation (p = 0.03).alter the elongation rate or overall extent of aggregation. Polymerization kinetics of hT40
(A). The ﬁrst 60 min of the aggregation reaction shown in Panel A is displayed in (B) to
ght (iS) and polymerization curves were ﬁt to Gompertz sigmoid function (curve ﬁt data
Fig. 2. Pseudophosphorylation at S422 did not alter the type or extent of aggregate formation. (A–B) Electron micrographs of hT40 (A) and S422E (B) diluted to 1.6 μM provide
representative images of the aggregate population. Scale bar = 400 nm. (C–E) Quantitative EM analysis of total aggregate mass per ﬁeld (C), mean aggregate length (D), and aggregate
number per ﬁeld (E) revealed no statistical differences between hT40 and S422E. Within each construct, there were signiﬁcantly more oligomeric aggregates (circles) than short
ﬁlaments (squares) or long ﬁlaments (triangles), but no difference between the numbers of short and long ﬁlaments. Values are expressed as mean ± SEM. n = 3 samples/group, 5
replicate images used per sample. Data were analyzed using a 2-way analysis of variance with the Holm-Sidak post-hoc test. *p ≤ 0.05 vs. oligomers of the same construct.
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monomers and aggregates
Vesicle motility assays in isolated squid axoplasm were used to
evaluate whether S422 pseudophosphorylation modulates the toxic
effect of tau aggregates on FAT (Brady et al., 1993; Morﬁni et al.,
2007). Vesicle motility was monitored for 50 min following perfu-
sion of 2 μM hT40 monomer (Fig. 5A), hT40 aggregates (Fig. 5B),
S422E monomer (Fig. 5C), or S422E aggregates (Fig. 5D). Differences
between groups were compared using average FAT rate (μm/s) over
the last 20 min of the assay (Fig. 6A, B). As previously reported, per-
fusion of hT40monomer had no effect on the rate of anterograde FAT
in the squid axoplasm (Fig. 5A), whereas perfusion of hT40 aggre-
gates signiﬁcantly inhibited anterograde FAT as compared to hT40
monomer (Fig. 5B; Fig. 6A; p = 0.003) (LaPointe et al., 2009b). Nei-
ther hT40 monomers nor hT40 aggregates altered the rate of retro-
grade FAT (Fig. 5A, B; Fig. 6B). In contrast to hT40 monomer,
perfusion of S422E monomer selectively inhibited anterograde
transport (Fig. 5C; Fig. 6A; p = 0.028), but not retrograde FAT. Sur-
prisingly, aggregated S422E signiﬁcantly inhibited both anterograde
and retrograde FAT rates (Fig. 5D; Fig. 6A, B) compared to S422E
monomer (anterograde, p = 0.012; retrograde, p = 0.002) and
hT40 aggregates (retrograde only, p = 0.019).
We also performed a linear regression analysis of FAT rates over the
50min assay and compared the slope of ﬁtted lines to evaluate whether
the rate of change in transport velocity was different among the treat-
ment groups (all average slopes were negative; Fig. 6C, D). The slopes
of hT40 aggregates (m = −0.008) and S422E aggregates
(m=−0.011) were signiﬁcantly different from their respectivemono-
mer samples (Fig. 6A; hT40 monomer, m = −0.002, r2 = 0.17, p =
0.003; S422E monomer, m =−0.005, r2 = 0.20, p= 0.001), but hT40
and S422E aggregates were not signiﬁcantly different when compared
(p = 0.243). The slopes for anterograde FAT in the S422E and hT40
monomer samples were statistically similar (Fig. 6C; p = 0.243). The
slope for retrograde transport in S422E aggregate-treated axoplasms
(m = −0.008) was signiﬁcantly different from S422E monomer-treated samples (Fig. 6D; m = −0.002, r2 = 0.12, p = 0.015), while
the slope for retrograde hT40 monomer and aggregates was not differ-
ent (p= 0.289). The slopes for retrograde transport in the hT40 aggre-
gate (m =−0.004) and S422E aggregate groups (Fig. 6D; p= 0.176)
were not statistically distinguished from each other.
3.5. pS422 tau colocalizes with TOC1 and TNT1 tau in AD
Triple-label IF confocal microscopy (Fig. 7A–D) and sandwich ELISAs
(Fig. 7E–G) were used to evaluate colocalization of pS422 with TOC1
and TNT1 in post-mortem AD brains. Staining in ﬁxed tissue sections
conﬁrmed several previous reports (Kanaan et al., 2016; Mufson et al.,
2014; Patterson et al., 2011a) that pS422 (Fig. 7A) extensively colocal-
izes with TNT1 (Fig. 7B) and TOC1 (Fig. 7C) in both control and AD
brains, despite the relatively sparse appearance of tau pathology in the
temporal cortices of control cases (data not shown). Sandwich ELISAs
were developed to examine the co-occurrence of pS422 with either
TNT1 or TOC1 in the same tau species isolated from the soluble fraction
of control and AD frontal cortices. The amount of total tau capturedwith
pS422 (detected with the pan-tau antibody, Tau5) was signiﬁcantly
higher in AD compared to control (Fig. 7E; t10 = 6.07, p = 0.0001).
The level of pS422 tau that also contained PAD exposed tau (i.e., TNT1
reactive) was signiﬁcantly higher in AD compared to control (Fig. 7F;
t10 = 2.31, p = 0.0435). Similarly, the level of pS422 tau that also
contained an oligomeric conformation (i.e., TOC1 reactive) was signiﬁ-
cantly higher in AD compared to control (Fig. 7G; t10 = 1.51, p =
0.0029).
4. Discussion
Phosphorylation of tau protein at residue S422 is a disease-related
modiﬁcation (Bussière et al., 1999; Hasegawa et al., 1996) that occurs
very early in AD, prior to NFT formation (Guillozet-Bongaarts et al.,
2006; Kimura et al., 1996). Despite an appreciation for the presence of
pS422 in disease, a mechanistic link between pS422 and neuronal dys-
function, or degeneration, was not yet established. Previously, we
Fig. 3.Aggregation of both hT40 and S422E tau produces oligomers and exposure of theN-
terminal phosphatase-activating domain. (A–C) Sandwich ELISAs were used to evaluate
(A) total tau using the monoclonal Tau5 antibody, (B) PAD exposure using the
monoclonal TNT1 antibody, or (C) oligomer formation using the monoclonal TOC1
antibody as the capture antibodies. Tau aggregates (black bars) exhibited signiﬁcantly
more reactivity for both TOC1 and TNT1 as compared to monomer (white bars),
however, there were no signiﬁcant differences between hT40 and S422E aggregates or
hT40 and S422E monomers. Values are expressed as mean ± SEM. n = 4/group. Data
were analyzed using a 2-way analysis of variance with the Holm-Sidak post-hoc test.
*p ≤ 0.05 vs. monomer of the same construct.
Fig. 4. Pseudophosphorylation of S422 increases SDS-stable dimer formation. (A) A
representative immunoblot of monomeric (M, i.e., unaggregated) and aggregated (A)
hT40 and S422E tau proteins probed with the monoclonal tau antibody Tau13 (total
tau). Monomers (~64 kDa) are similar across all samples and dimers (~180 kDa) are
present in aggregated tau samples. (B–C) Quantitative analysis of immunoblot signal
intensity. There were equivalent levels of tau in the monomer band (B) for both
monomeric (M, i.e., unaggregated) and aggregated (A) hT40 and S422E samples.
Aggregation of tau protein increased the intensity of the dimer band (C) in both hT40
and S422E, and there were signiﬁcantly more tau dimers in the aggregated S422E
samples when compared to aggregated hT40 (p = 0.03). Values are expressed as
mean ± SEM. n= 4/group. Data were analyzed using a 2-way analysis of variance with
a Holm-Sidak post-hoc test. *p ≤ 0.05 vs. monomer of the same construct, and **p ≤ 0.05
vs. hT40 aggregates.
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with early markers of tau toxicity, including oligomer formation
(Mufson et al., 2014; Patterson et al., 2011a) and exposure of the N-ter-
minal PAD (Kanaan et al., 2016). Here, we extended these previous im-
munohistochemical reports by demonstrating colocalization of pS422
with both TOC1 and TNT1 in situ and in tau species isolated from
human brain tissue. Additionally, we have characterized the aggrega-
tion kinetics of S422E tau, and demonstrated that this modiﬁcation sta-
bilizes the formation of multimeric tau species. Further, S422E tau
aggregates inhibited both anterograde and retrograde FAT in squidaxoplasms. Collectively, these ﬁndings identify potential mechanisms
by which phosphorylation of tau at S422 may contribute to toxicity in
AD.
4.1. The effect of S422 pseudophosphorylation on tau aggregation
Puriﬁed recombinant tau protein does not detectably aggregate over
days of incubation under physiological conditions (King et al., 1999).
However, aggregation can be accelerated in vitro by incubation with
an anionic inducer, such as ARA (Chirita et al., 2003; Wilson and
Binder, 1997). When induced, tau polymerization typically follows nu-
cleation-dependent kinetics, characterized by a nucleation phase (i.e.,
lag time), followed by a more extended phase of exponential growth,
before reaching a steady-state equilibrium (Chirita and Kuret, 2004).
Nucleation follows a ligand-mediated mechanism, whereby inducer in-
teraction stabilizes an altered conformation of tau that then undergoes
self-aggregation (King et al., 1999; Necula and Kuret, 2004b). Results
from the present analysis demonstrated that pseudophosphorylation
of S422 increased the lag time of tau polymerization without altering
the rate of elongation or maximum polymerization signal. Additionally,
aggregates formed by S422E tau and hT40 tau had similar morphology,
and showed comparable levels of β-sheet structures (i.e., ThS signal).
Collectively, these observations suggest that S422E may prolong aggre-
gate nucleation, but once elongation is initiated the aggregation reac-
tion proceeds similarly to wild-type tau protein.
Previously, pseudophosphorylation in the C-terminal domain of tau,
including S422E and S409E, was found to have little effect on tau
Fig. 5. Vesicle motility assays in isolated squid axoplasm. Individual velocity (μm/s) measurements (arrowheads) are plotted as a function of time (min). (A) Perfusion of hT40monomer
did not alter anterograde (▶) or retrograde ( ) FAT. (B) Perfusion of hT40 aggregates selectively inhibited anterograde but not retrograde FAT. (C) Perfusion of S422Emonomer selectively
inhibited anterograde FAT. (D) Aggregates of S422E inhibited both anterograde and retrograde FAT.
325C.T. Tiernan et al. / Experimental Neurology 283 (2016) 318–329polymerization (Necula and Kuret, 2004a). For example, aggregated
S422E or S409E accumulated a similar amount of ﬁlamentous tau rela-
tive to full-length wild-type tau, whereas mutations clustered near the
proline-rich domain (i.e., S212E/S214E, S199E/S202E/T205E) enhanced
ﬁlament mass by 2–3-fold (Necula and Kuret, 2004a). Our results are
consistent with these observations, and support the hypothesis that
modiﬁcations in various locations along the polypeptide chain differen-
tially affect tau aggregation (Necula and Kuret, 2004a, 2005). The ob-
served increase in lag time could indicate that pseudophosphorylation
at S422 impedes the ability of ARA to interact with tau (King et al.,
1999), or decreases the ability of tau to adopt a speciﬁc ﬁlament assem-
bly-competent conformation (Necula and Kuret, 2004b). The stabiliza-
tion of dimers further supports the notion that S422 modiﬁcation has
an impact on the structures formed during tau aggregation in vitro,
but ultimately the ﬁnal aggregated sample is comparable to wild-type
tau by several measures. Since pS422 is known to colocalize with
pretangle pathology (Guillozet-Bongaarts et al., 2006; Kimura et al.,
1996; Mufson et al., 2014; Patterson et al., 2011a), these in vitro results
suggest that this modiﬁcation may contribute more to the stabilization
of pre-ﬁbrillar conformations rather than directly facilitating ﬁlament
elongation.
4.2. A novel role for S422 pseudophosphorylation in tau dimer stabilization
Accumulating evidence suggests that multimeric species of tau
that precede NFTs are responsible for neuronal dysfunction and de-
generation. For instance, reducing tau overexpression in the
rTg4510 transgenic mouse decreases neuronal cell loss even though
ﬁlamentous inclusions continue to form (Santacruz et al., 2005), and
multimeric tau species correlate with spatial memory deﬁcits
(Berger et al., 2007). Similarly, in human brain tissue, levels of gran-
ular tau oligomers are elevated, even in Braak stage I–II control cases
(Maeda et al., 2006, 2007; Patterson et al., 2011a) with limited NFT
pathology (Braak and Braak, 1997).
In the present study, aggregation of hT40 or S422E produced de-
tectable SDS-stable tau multimers migrating as a major band with an
apparent molecular weight of 180 kDa. The 180 kDa band has been
previously identiﬁed as a tau dimer by SELDI-TOFmass spectrometry(Patterson et al., 2011a; Sahara et al., 2007). S422E enhanced formation
of the 180 kDa dimer as compared to hT40 suggesting that phosphory-
lation at this residue stabilizes a dimeric tau conformation. These di-
mers also corresponds to the SDS-stable species (~140 and 170 kDa)
described in the rTg4510 transgenic mouse, although the sizes are
slightly different since our recombinant tau construct contains a histi-
dine tag (Berger et al., 2007; Sahara et al., 2007, 2013). Berger et al.
(2007) demonstrated that these dimeric forms of tau are abnormally
phosphorylated, including phosphorylation at S422, and theywere neg-
atively correlated with spatial memory performance in the Morris
water maze. Despite S422E-mediated stabilization of tau multimer for-
mation, TOC1 reactivity was not increased in comparison to hT40. One
possible explanation for this is that TOC1 appears to label only a sub-
population of oligomeric aggregates (Patterson et al., 2011a). Hence,
more than one tau oligomer conformation is likely to exist, and S422E
may stabilize one or more multimer conformations not detected by
the TOC1 antibody. The lack of differences in levels of PAD exposure be-
tween hT40 and S422E aggregate samples is consistent with the forma-
tion of similar levels and morphologies of tau polymers by the end of
the in vitro polymerization assay. Taken together, these results indicate
that S422 phosphorylation facilitates the formation of SDS-stable tau
dimers.
4.3. Coincidence of pS422, PAD exposure, and oligomer formation in AD
Co-localization between pS422, TNT1 and TOC1was extensive in the
temporal cortex of AD brains, consistent with previous reports
(Guillozet-Bongaarts et al., 2006; Kanaan et al., 2016; Mufson et al.,
2014; Patterson et al., 2011a). The sandwich ELISAs captured pS422-re-
active tau species and then used TNT1 and TOC1 to detect whether the
pool of pS422 tau also contained PAD exposed and oligomer tau species,
respectively. These are the ﬁrst data to conﬁrm that thesemodiﬁcations
coexist on the same tau species. Interestingly, low total levels of tau
with pS422 were captured from age-matched control brains in the
ELISAs, and the data suggest that the majority of the pS422 tau in con-
trols (~0.1 ng/μl) is reactive with TNT1 and TOC1, further supporting a
close association between these modiﬁcations even in control brains.
Together, these data conﬁrm that pS422 tau species also exhibit
Fig. 6. Pseudophosphorylation of S422 inhibits anterograde and retrograde fast axonal
transport (FAT). (A–B) Quantiﬁcation of average anterograde and retrograde FAT rates
during the last 20 min of Fig. 5A–D indicates that hT40 aggregates, S422E monomers,
and S422E aggregates all signiﬁcantly inhibit anterograde FAT (A) compared to ht40
monomers, whereas only S422E aggregates signiﬁcantly inhibit retrograde FAT (B). (C–
D) Data in Fig. 5A–D were ﬁt using linear regressions and the slopes were compared to
assess the rate of change in transport velocity (all average slopes were negative). The
rate of decline in anterograde transport (C) in hT40 and S422E aggregate treated
axoplasms is signiﬁcantly different compared to axoplasms treated with their respective
monomer samples. Anterograde rates of decline did not differ between axoplasms
treated with hT40 or S422E aggregates. The rate of change in retrograde transport (D) in
S422E aggregates is different from S422E monomers. All differences between groups
were compared using a 2-way analysis of variance with a Holm-Sidak post-hoc test.
*p ≤ 0.05.
Fig. 7. Phosphorylation at S422 occurs with PAD exposure and oligomer formation in
Alzheimer's disease. (A–D) Triple label immunoﬂuorescence conﬁrmed that pS422
(blue, A), TNT1 (green, B) and TOC1 (red, C) are highly colocalized in AD temporal lobe
tissue (merge, D). The coincidence of pS422, TNT1 and TOC1 was evident in both
neuronal (arrowheads) and thread (arrows) inclusions. Scale bar in D is 50 μm and
applies to A–D. (E–G) Novel sandwich ELISAs were developed to capture pS422 positive
tau species from the soluble fraction of control (i.e., age-matched non-demented) and
AD frontal cortex (n = 6/group). (E) The total amount of tau captured with pS422
antibody was signiﬁcantly higher in AD compared to controls (detected with Tau5, a
pan-tau antibody). (F) The amount of pS422 tau with PAD exposed tau was signiﬁcantly
higher in AD compared to control (detected with TNT1, a marker of PAD exposure). (G)
The amount of pS422 that was oligomeric was signiﬁcantly greater in AD compared to
controls (detected with TOC1, a tau oligomer selective antibody). Data were compared
using an unpaired t-test. *p ≤ 0.05.
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linked to tau-mediated transport toxicity (Kanaan et al., 2011, 2012,
2016; LaPointe et al., 2009b; Mufson et al., 2014; Patterson et al.,
2011a,b; Vana et al., 2011).
4.4. Inhibition of axonal transport by S422 pseudophosphorylation
Abnormalities in kinase activity and deﬁcits in FAT, a cellular process
critical for the maintenance of appropriate neural connectivity, are in-
creasingly implicated in the pathogenesis of various neurodegenerative
diseases, including AD and tauopathies (Morﬁni et al., 2002a, 2009a).
Dystrophic neurites, synaptic loss, and mislocalization of proteins are
early pathogenic AD features consistent with this hypothesis (Bell and
Claudio Cuello, 2006; Dessi et al., 1997; Scheff et al., 1990), but relation-
ships among these critical pathogenic events remained unclear. Recent-
ly, our group described a mechanism by which physiological levels of
aggregated tau inhibits kinesin-dependent anterograde FAT (Kanaan
et al., 2011, 2012; LaPointe et al., 2009b). This effect is mediated by N-
terminal amino acids 2–18 (Kanaan et al., 2011), comprising the PAD.
Increased PAD exposure activates a protein phosphatase-1/glycogen
kinase-3 (PP1/GSK3) signaling cascade that, in turn, promotesphosphorylation of conventional kinesin and detachment from its
transported cargoes (Kanaan et al., 2011, 2012; LaPointe et al., 2009b).
Collectively, these ﬁndings provided a mechanistic basis linking abnor-
mal kinase activation, aberrant tau phosphorylation, and neuritic atro-
phy in AD (Kanaan et al., 2013; Morﬁni et al., 2002a).
Our results indicate that both monomeric and aggregated S422E in-
hibit anterograde FAT in the squid axoplasm model. These ﬁndings are
consistent with other disease-related forms of tau where increased
PAD exposure was predicted in monomers. For example, mimicking
the phosphoepitope of AT8 (i.e., S199E/S202E/T205E) impairs folding
of the amino terminus in the paperclip conformation (Deters et al.,
2009; Gotz et al., 2001; Grueninger et al., 2010; Grundke-Iqbal et al.,
1986a, b; Jeganathan et al., 2006; Kosik et al., 1986; Wood et al., 1986)
and this protein inhibited anterograde FAT as a monomer (Kanaan et
al., 2011; LaPointe et al., 2009b; Spillantini and Goedert, 1998).
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frontotemporal dementia that lacks exons 6–9 (including the proline-
rich region) also inhibited anterograde FAT as a monomer. This protein
is unlikely to form the paperclip conformation because the hinge region
is eliminated, ultimately increasing PAD exposure. The effects of S422E
aggregates and monomers on anterograde FAT are likely due to the
PAD-dependent activation of PP1/GSK3 pathway previously identiﬁed
(Bierer et al., 1995; Biernat et al., 1993; Drewes et al., 1995; Kanaan et
al., 2011, 2012; LaPointe et al., 2009b), but future studies are necessary
to directly conﬁrm this conclusion.
Unexpectedly, we observed a toxic effect of S422E aggregates on
retrograde FAT, a unique effect among all tau constructs tested to
date in the isolated squid axoplasm preparation (Kanaan et al.,
2011, 2012; LaPointe et al., 2009b; Morﬁni et al., 2007;
Morishima-Kawashima et al., 1995; Patterson et al., 2011b). Based
on results from biochemical analyses here, S422E-mediated inhibi-
tion of retrograde FAT may result from activation of kinases other
than GSK3, which selectively inhibits only anterograde FAT (Berger
et al., 2007; Kopeikina et al., 2011; Maeda et al., 2007; Matsuo et
al., 1994; Morﬁni et al., 2002b; Patterson et al., 2011a; Sahara et al.,
2013). Accordingly, several phosphotransferases inhibit both anter-
ograde and retrograde FAT through multiple mechanisms in the axo-
plasm preparation (Kanaan et al., 2013; Kimura et al., 1996; Morﬁni
et al., 2006, 2009b; Patterson et al., 2011a; Pigino et al., 2009;
Stoothoff and Johnson, 2005; Ward et al., 2013). Given these prece-
dents, it is conceivable that one or more of the phosphotransferases
responsible for phosphorylation of S422 in situ (i.e., JNK and p38)
(Guillozet-Bongaarts et al., 2006; Kimura et al., 1996; Mufson et al.,
2014; Reynolds et al., 1997a,b; Vana et al., 2011; Yoshida et al.,
2004) could indirectly promote FAT deﬁcits, but the precise mecha-
nism of this effect remains to be identiﬁed.
The squid axoplasmmodel system used here provides an opportuni-
ty to study axon-autonomous effects because the axoplasm is isolated
from the somatodendritic compartment and synapses. In addition to
the mechanism described above, various kinase-independent mecha-
nisms have been proposed to inhibit FAT that could be alternate expla-
nations for S422E effects. Because phosphorylation at S422 is unlikely to
negatively affect microtubule afﬁnity, monomers of this modiﬁed form
of tauwould be in position to impair axonal transport throughmore di-
rect interactions with motor proteins on microtubules. Some studies
have proposed that tau can regulate motor protein binding to microtu-
bules or physically block motor proteins (Ebneth et al., 1998;
Mandelkow, 2003; Seitz et al., 2002; Trinczek et al., 1999), but our pre-
vious studies found that application of normal tau monomers up to ap-
proximately 20-fold higher than physiological levels does not
negatively affect transport in either direction in the squid axoplasm
assay used here (Morﬁni et al., 2007). Moreover, aggregates of S422E,
which would not be expected to bind microtubules, are more potent
in affecting FAT. Another proposed mechanism involves alterations of
transcription or translation but these are also unlikely to contribute to
these effects because the axoplasm model is isolated from the
somatodendritic compartment and synapses.
In addition to its effects on FAT, these studies do not rule out the pos-
sibility that pS422 tau could exert toxicity through alternate pathways.
Other proposedmechanisms for neurotoxicity include enhanced forma-
tion of degradation-resistant multimers that could overwhelm protein
degradation machinery (Myeku et al., 2015; Tai et al., 2012; Wang et
al., 2009) and/or compromise chaperone activity (Patterson et al.,
2011a), impairment of neurophysiological functions (Fá et al., 2016),
or promotion of mitochondria dysfunction (Kopeikina et al., 2011).
However, the relatively low concentrations of S422E tau and the short
incubation time used presently would argue against these mechanisms
as an explanation for the effects on FAT. Finally, PAD-dependent effects
on synaptic function (Moreno et al., 2016) could be enhanced by pS422.
Additional studies are required to establish whether S422E tau plays a
role in one or more of these alternative pathways of toxicity.5. Conclusions
In summary, the present work using S422E tau identiﬁes three po-
tential effects of pS422-modiﬁed tau relevant to AD. First, S422E slows
the nucleation phase of tau aggregation. Delayed ﬁlament formation
may stabilize pre-ﬁbrillar tau conformations that contribute to toxicity.
Second, S422E facilitates the formation of stable tau dimers. Whether
these two mechanisms are related is currently unknown; however the
observation that phosphorylation at a single residue can stabilize tau
multimer conformations known to contribute to disease (Berger et al.,
2007; Bussière et al., 1999; Guillozet-Bongaarts et al., 2006; Hasegawa
et al., 1996; Jeganathan et al., 2008; Kanaan et al., 2011, 2012;
LaPointe et al., 2009a;Necula andKuret, 2005) is novel. Finally, we iden-
tify a unique effect of aggregated S422E tau on FAT. Not only is S422E
tau capable of inhibiting anterograde FAT as a monomer and aggregate,
but it also is capable of inhibiting retrograde FAT when aggregated. In-
terestingly, the mechanism of this retrograde inhibition remains to be
identiﬁed and is likely PAD-independent, as S422E does not appear to
expose PAD to a greater extent than wild-type tau. In combination
with our data fromhumanAD brains, these results reveal a novel mech-
anistic link between tau phosphorylation at S422 and toxicity in AD.Funding
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